Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CIML-NK cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
CIML-NK cells are allogeneic cytokine-induced memory-like natural killer (CIML-NK) cells, which potentially enhance cytotoxic anti-tumor immune response (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C148213 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + CIML-NK cells + Venetoclax | Aldesleukin CIML-NK cells Venetoclax | 0 | 1 |
CIML-NK cells | CIML-NK cells | 0 | 1 |
CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept | CIML-NK cells Ipilimumab Nogapendekin alfa inbakicept | 0 | 1 |
CIML-NK cells + Nogapendekin alfa inbakicept | CIML-NK cells Nogapendekin alfa inbakicept | 0 | 3 |